The approval, effective as of February 28, 2024, allows the company to begin its U.S. clinical trial, named HYPER-H23-1, aimed at evaluating the safety and efficacy of DehydraTECH-CBD in patients with …
Bringing you TOP Pot Stocks!
Bringing you TOP Pot Stocks!
The approval, effective as of February 28, 2024, allows the company to begin its U.S. clinical trial, named HYPER-H23-1, aimed at evaluating the safety and efficacy of DehydraTECH-CBD in patients with …
Recent Comments